Evidence map›Paper›PMID 32647567›Full record

ReviewHepatic oncology2020

Recent advances of GOLM1 in hepatocellular carcinoma.

Jiuliang Yan, Binghai Zhou, Hui Li, Lei Guo, Qinghai Ye

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hepatic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Frontiers in bioengineering and biotechnology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jiuliang YanDepartment of Liver Surgery & Transplantation, Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Binghai ZhouDepartment of Liver Surgery & Transplantation, Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Hui LiDepartment of Liver Surgery & Transplantation, Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lei GuoDepartment of Liver Surgery & Transplantation, Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Qinghai YeDepartment of Liver Surgery & Transplantation, Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common liver malignancies and is a leading cause of cancer-related deaths. Most HCC patients are diagnosed at an advanced stage and current treatments show poor therapeutic efficacy. It is particularly urgent to explore early diagnosis methods and effective treatments of HCC. There are a growing number of studies that show GOLM1 is one of the most promising markers for early diagnosis and prognosis of HCC. It is also involved in immune regulation, activation and degradation of intracellular signaling factors and promotion of epithelial-mesenchymal transition. GOLM1 can promote HCC progression and metastasis. The understanding of the GOLM1 regulation mechanism may provide new ideas for the diagnosis, monitoring and treatment of HCC.

Indexed as

diagnosisGOLM1hepatocellular carcinomaimmune systemprognosis

Identifiers

PMID32647567
PMCPMC7336318
OpenAlexW3039385184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.